Improved Inactivated Influenza Vaccine
Inactivated influenza vaccine with enhanced cross protection (Flu-ECP™)
Current inactivated influenza vaccines are strain-specific and poorly effective against variant or mismatched viruses. They are standardized based on the hemagglutinin (HA) protein of the influenza virus, the key protective antigen.
This improved inactivated influenza vaccine (Flu-ECP) is based on the principle of targeting the conserved domains. It uniquely achieves an increased exposure of conserved domains in HA by properly altering the HA structure. This vaccine, when properly formulated, will not only provide the strain-specific protection as the current inactivated vaccine, but also an enhanced cross protection against variant viruses. As it is based on current vaccines, it can be potentially developed faster and readily incorporated into the current influenza immunization program. It is particularly advantageous in countering the vaccine mismatch which frequently occurs during influenza seasons.
Current inactivated influenza vaccines are strain-specific and poorly effective against variant or mismatched viruses. They are standardized based on the hemagglutinin (HA) protein of the influenza virus, the key protective antigen.
This improved inactivated influenza vaccine (Flu-ECP) is based on the principle of targeting the conserved domains. It uniquely achieves an increased exposure of conserved domains in HA by properly altering the HA structure. This vaccine, when properly formulated, will not only provide the strain-specific protection as the current inactivated vaccine, but also an enhanced cross protection against variant viruses. As it is based on current vaccines, it can be potentially developed faster and readily incorporated into the current influenza immunization program. It is particularly advantageous in countering the vaccine mismatch which frequently occurs during influenza seasons.